



biblio.ugent.be

The UGent Institutional Repository is the electronic archiving and dissemination platform for all UGent research publications. Ghent University has implemented a mandate stipulating that all academic publications of UGent researchers should be deposited and archived in this repository. Except for items where current copyright restrictions apply, these papers are available in Open Access.

This item is the archived peer-reviewed author-version of:

Title:

Synthesis and Evaluation of 5'-Modified Thymidines and 5-Hydroxymethyl-2'-Deoxyuridines as M. tuberculosis Thymidylate Kinase Inhibitors

Author(s): Kiran S. Toti, Frederick Verbeke, Martijn D. P. Risseeuw, Vladimir Frecer, H el ene Munier-Lehmann, Serge Van Calenbergh

Source: BIOORGANIC & MEDICINAL CHEMISTRY (2013) , 21 (1), 257-268 **DOI:** 10.1016/j.bmc.2012.10.018

Synthesis and Evaluation of 5'-Modified Thymidines and 5-Hydroxymethyl-2'-Deoxyuridines as *M. tuberculosis* Thymidylate Kinase Inhibitors

Kiran S. Toti,¹ Frederick Verbeke,¹ Martijn D. P. Risseeuw,¹ Vladimir Frecer,² H  l  ne Munier-Lehmann,³ Serge Van Calenbergh^{1,*}

¹Laboratory for Medicinal Chemistry Faculty of Pharmaceutical Sciences (FFW), Ghent University, Harelbekestraat 72, 9000 Ghent, Belgium.

²Department of Physical Chemistry of Drugs, Faculty of Pharmacy, Comenius University, 83232 Bratislava, Slovakia.

³Institut Pasteur, Unit   de Chimie et Biocatalyse, 28 rue du Dr Roux, 75724 Paris Cedex 15, France.

⁴ CNRS UMR3523, 28 rue du Dr Roux, France.

Corresponding author: Tel.: +32 9 264 81 24; fax: +32 9 264 81 46. E-mail address: serge.vanalenbergh@ugent.be (S. Van Calenbergh)

GRAPHICAL ABSTRACT

Keywords: *M. tuberculosis*, thymidine monophosphate kinase, inhibitors, nucleoside analogues, 5-hydroxymethyl pyrimidines, phosphate bioisosteres.

ABSTRACT

We report the synthesis of 5'-modified thymidines (**16**, **18**, **21**, **23**) and 5,5'-bis-substituted 2'-deoxyuridine analogues (**30**, **47**) as inhibitors of thymidine monophosphate kinase of *Mycobacterium tuberculosis* (TMPK_{mt}). These analogues were evaluated for their capacity to inhibit **TMPK_{mt}** and solely two 5'-modified thymidines were found to possess moderate inhibitory activity. In addition, a feasibility study of protecting groups for the 5-CH₂OH moiety of 2'-deoxyuridines is described that enables to introduce the desired 5'-modification.

INTRODUCTION

Tuberculosis (TB) is responsible for more than 2 million human deaths annually. The emergence of multi-drug and extremely drug resistant TB strains asks for new drugs preferably acting on yet unaddressed targets [1]. The knowledge of the TB genome should enable to reveal new metabolic pathways and targets, which may fuel the discovery process of antituberculosis drugs [2]. Phosphorylation of nucleosides is a prerequisite for DNA synthesis and the enzymes in charge are crucial for cell growth. Thymidine monophosphate kinase is situated at the junction of the *de novo* and salvage pathways for thymidine triphosphate (dTTP) synthesis. TMPK is the last specific enzyme in these pathways and has been recently validated in vivo as an antibacterial target [3]. We have focused our effort on the TMPK of *Mycobacterium tuberculosis* (TMPK_{mt}) for generating anti-TB drugs. Previously, we designed a number of promising TMPK_{mt} inhibitors such as the bicyclic inhibitor **1** and the 5'-thiourea-substituted α -thymidine analogue **2** (Figure 1) [4]. Furthermore, we showed that hydroxylation of the 5-methyl group of the TMP substrate (**3**) resulted in a moderately potent TMPK_{mt} inhibitor instead of substrate [5]. Mainly based on inhibitory data reported by our group, Frecer *et al.* recently reported on the combinatorial design and structure-based in silico screening of a virtual focused library of bicyclic thymidine analogs in an effort to identify more potent TMPK_{mt} inhibitors [6]. In their study they used the threedimensional structure of TMPK_{mt} complexed with 5-hydroxymethyl-dUMP (**3**) to develop a QSAR model, to parameterize a target-specific scoring function for TMPK_{mt} and to select virtual hits which display the highest predicted binding to the target. Compound **4** emerged as one of the best analogues. The binding of **4** to TMPK_{mt} is predicted to be similar to that of **1**. Beside the fact that it is a carba-nucleoside contains a sulfondiamide group replacing the thiourethane moiety of the condensed ring of **1**, **4** differs from **1** by the presence of a 5-CH₂OH group, known to possibly make an extra hydrogen bond with a water molecule (W12) or with the side chain of

Ser99, and a 5'-(N-methylsulfamoyl)methyl moiety. The latter fragment, which replaces the phosphate moiety present in TMP, was anticipated to favorably interact Arg95, Arg153 and especially with the magnesium ion. Alternative phosphate isosters suggested in the Freceer publication are a 5-tetrazolylmethyl and methylsulfonylmethyl group. In this pilot study we decided to explore the importance of the proposed 5-CH₂OH and 5'-modifications for **TMPK_{mt}** inhibition.

Figure 1

Figure 1. Selected promising TMPK_{mt} inhibitors designed previously in our laboratory (**1**, **2**, and **3**) [4,5] or predicted by a QSAR model (**4**) [6]. K_i^{exp} and K_i^{pre} indicate experimental and predicted K_i values, respectively. The K_m value for dTMP is 4.5 μ M.

RESULTS AND DISCUSSION

Chemistry

We envisioned synthesizing the target molecules using a Wittig-Horner reaction to introduce the desired 5'-modifications as a key step. For this purpose two non-commercial Horner reagents were self-made (Scheme 1). Diethyl ((methylsulfonyl)methyl)phosphonate **6** was prepared according to known procedures [7], while Horner reagent **9** was obtained by reacting

half an equivalent of chlorodiethylphosphate with bis-lithiated **8** [8,9]. 3'-Silylated thymidine **12** was produced by a selective cleavage of the primary TBDMS group on **11** [10,11].

Scheme 1. Synthesis of Horner reagents **6** and **9**, and intermediate **14**. *Reagents and conditions:*(a) THF, BuLi, -78 °C, 1h, diethylchlorophosphate (0.5 eq), -78 °C→0 °C, 1h, 65 %; (b) THF, pyridine, HF-pyridine, 0 °C, 1h, 0 °C→rt, 1h, 36 %.

To synthesize the 5'-modified thymidines **16**, **18**, **21** and **23** (Scheme 2), the 5'-OH group of **12** was oxidized using Dess-Martin periodinane and the resulting aldehyde **13** was reacted with the proper Wittig-Horner reagents to give **14**, **17** and **19** in moderate yields.

Methylsulfone **16** was obtained by Pd catalyzed hydrogenation of **14**, followed by the removal of TBDMS group. The conjugated double bond in **17** was reduced using NaBH₄/NiCl₂ [12] and the product was desilylated using TBAF affording **18**. Conjugate reduction of nitrile **19** was achieved with NaBH₄ in a pyridine-methanol mixture at elevated temperature [13]. Deprotection of **20** afforded the 6'-nitrile analogue **21** in 76% yield. A cycloaddition between nitrile **20** and TMSN₃ in the presence of dibutyltin oxide gave **22** in moderate yield [14]. Even though the conversion of **20** to **4** was complete (by LCMS), the isolated yield is lowered by the elaborate purification necessary to isolate the product [15].

Scheme 2. Synthesis of the 5'-modified thymidines. *Reagents and conditions:* (a) CH₂Cl₂, Dess-Martin periodinane, rt, 4h; (b) THF, **6**, BuLi, -78 °C, 15 min, -78 °C, 1h, rt, 18h, 20% from **12**; (c) H₂, Pd-C, MeOH, 4h, rt; (d) THF, TBAF, 40 °C, 15h, 20% over two steps; (e) THF, **9**, BuLi, -78 °C, 1h, -78 °C, 1h, rt, 18h, 48% from **12**; (f) (i) MeOH-THF (5:1), NiCl₂, NaBH₄, 0 °C, 1h; (ii) THF, TBAF, 40 °C, 1h, 12% over two steps; (g) THF, cyanomethyltriphenylphosphonium chloride, BuLi, 0 °C, 30 min, 0 °C→rt, 18h, 57% from **12**; (h) pyridine-MeOH (3:1), NaBH₄, 120 °C, 4h, 53%; (i) THF, TBAF, rt, 4h, 76%; (j) toluene, TMSN₃, Bu₂SnO, 110 °C, 4h, 32%; (k) THF, TBAF, rt, 4h, 34%.

Hydroxymethylation at position 5 of dU (**24**) of pyrimidine is reported. However, selective protection of this hydroxyl group appears difficult [16]. An attempt to hydroxymethylate the 5-position of **25** failed, possibly due to the low solubility of the substrate in formalin-triethylamine system and the lability of the TBDMS groups under the harsh reaction conditions. Hence, we decided to introduce the 5-CH₂OH group after modifying the 5'-position in 2'-deoxyuridine (Scheme 3). As a model substrate for this strategy, compound **29** was synthesized smoothly using similar transformations as before. Unfortunately, reaction of **29** with formaldehyde at elevated temperature was very slow with only traces of the desired

product formed after several days, while under microwave conditions, the starting material degraded.

Scheme 3. Attempted hydroxymethylation route to **30**. *Reagents and conditions:* (a) THF, pyridine, HF-Pyridine, 0 °C, 1h, 0 °C→rt, 1h, 53 %; (b) (i) CH₂Cl₂, Dess-Martin periodinane, rt, 4h; (ii) THF, cyanomethyltriphenylphosphonium chloride, BuLi, 0 °C, 30 min, 0 °C→rt, 18h, 51% over two steps; (c) H₂, Pd-C, MeOH, 4h, rt; (d) THF, TBAF, rt, 4h, 73%; (e) paraformaldehyde, H₂O, TEA, 100 °C, 3 days or paraformaldehyde, H₂O, TEA, continuous irradiation of microwave from rt→150 °C in 3 min, 10 min at 150 °C.


Because of this setback, we decided to start from compound **31**, obtained via the benzylic bromide oxidation as reported by Grover *et al.* [10] (Scheme 4). Selective primary desilylation of **31** gave **32**. Attempted successive Dess-Martin and Wittig-Horner reactions involving two different Horner reagents failed to give the desired products.

Scheme 4. Attempted 5'-derivatization of acetyl protected 2'-deoxy-5-hydroxymethyluridine. *Reagents and conditions:* (a) anh. THF, pyridine, HF-pyridine, 0 °C, 1h, 0 °C→rt, 1h, 33 %; (b) (i) anh. CH₂Cl₂, Dess-Martin periodinane, rt, 4h; (ii) anh. THF, **6**, BuLi, -78 °C, 15 min, -78 °C, 1h, rt; (c) (i) anh. CH₂Cl₂, Dess-Martin periodinane, rt, 4h; (ii) anh. THF, cyanomethyltriphenylphosphonium chloride, BuLi, 0 °C, 30 min, 0 °C→rt.

At this point we chose to look for a suitable protecting group for the 5-hydroxymethyl moiety that is compatible with the reaction conditions used to modify the 5'-position and can also be removed under mild conditions. Towards this end 5-hydroxymethyl derivative **33** was synthesized according to a literature procedure [18].

BOM derivatization of **33** to **34** proceeded in 37% yield (Scheme 5). Since the desired product also features a benzylic hydroxyl group, we ran a model hydrogenation reaction on **34** with palladium as catalyst. Unsurprisingly, the reaction mainly afforded thymidine **11**, besides minor amounts (24 %) of **12**. Next, the use of a 2-(trimethylsilyl)ethoxymethyl (SEM) protecting group, known to be cleavable under mild conditions, was investigated. Compound **33** was converted to **35** in moderate yield. Selective removal of the primary TBS gave **36**, which on DMP oxidation followed by Horner reaction gave **37**. Unfortunately, attempts to remove both SEM groups with TBAF in anhydrous THF at elevated temperature failed.


Attempts to protect **33** as 4-methoxyphenol (PMP) ether under the Mitsunobu conditions led to degradation of the starting material. Conditions used to protect **33** with two 4-methoxybenzyl (PMB) groups afforded **38** only in low yields (13%), mainly because of simultaneous formation of compounds with three PMB & one TBS group and four PMB groups, leaving these protection methods unattractive.



Scheme 5. Screening viable protecting group for 5-hydroxymethyl-2'-deoxyuridine. *Reagents and conditions:* (a) DMF, DIPEA, BOM-Cl, 0 °C→rt, 16h, 37 %; (b) MeOH, H₂, Pd-C; (c) CH₂Cl₂, DIPEA, SEM-Cl, 40 °C, 6h, 50%; (d) THF, pyridine, HF-pyridine, 0 °C, 1h, 0 °C→rt, 1h, 38%; (e) (i) CH₂Cl₂, Dess-Martin periodinane, rt, 4h; (ii) THF, **6**, BuLi, -78 °C, 15 min, -78 °C, 1h, rt, 16h, 29% over two steps; (f) THF, TBAF, Δ; (g) THF, DEAD, triphenylphosphine, PMP, 0 °C→rt; (h) DMF, PMB-Cl, NaH, 0 °C→rt, 4h, 13%.

These problems finally led us to protect the 5-CH₂OH group of **33** as pivaloate ester in good yield (**Scheme 6**). A series of routine transformations was used to convert **39** into the acrylonitrile **41** in acceptable yields. Several conditions were evaluated to reduce the double

bond in **41**, including H_2 -Pd-C, $NaBH_4$ in pyridine and $NaBH_4$ - $NiCl_2$ in MeOH-THF. Unfortunately, all these methods led to deoxygenation of the 5- CH_2OH group and formation of a thymine base as a predominant side product. Attempts to remove the pivaloyl prior from **41** with tetrabutylammonium hydroxide gave undesired product **42**. Hydrogenation using platinum on carbon afforded **43** in 70 % yield. Subsequent removal of the TBDMS group with TBAF and the pivaloyl group with sodium methoxide gave **30** in excellent yield. Azidotrimethylsilane mediated cycloaddition of nitrile **43** gave **45** in 74% yield. Removal of the remaining protecting groups with NaOMe in methanol and NH_4F in methanol allowed obtaining **47** in excellent yield. For the desilylation NH_4F proved to be superior to TBAF with regard to purification of the final product.



Scheme 6. Synthesis of the 5'-modified 2'-deoxy-5-hydroxymethyluridine analogs **30** and **47**.
Reagents and conditions: (a) pyridine, DMAP, Piv-Cl, rt, 18h, 74%; (b) THF, pyridine, HF-

pyridine, 0 °C, 1h, 0 °C→rt, 1h, 59%; (c) (i) CH₂Cl₂, Dess-Martin periodinane, rt, 4h; (ii) anhydrous THF, cyanomethyltriphenylphosphonium chloride, -78 °C, BuLi, 30 min, -78 °C→rt, 18h, 82% over two steps; (d) THF, Bu₄NOH, rt, 5h, 40%; (e) MeOH, H₂, Pt-C, rt, 4h, 70%; (f) THF, TBAF, rt, 4h, 90%; (g) 0.5M NaOMe in MeOH, rt, 3h, 95%; (h) toluene, TMSN₃, Bu₂SnO, 110 °C, 4h, 74%; (i) 0.5M NaOMe in MeOH, rt, 3h, 92%; (j) NH₄F, MeOH, 50 °C, 2 days, 87%.

Biological results

The capacity of compounds **16**, **18**, **21**, **23**, **30** and **47** to inhibit **TMPK_{mt}** was assessed via a spectrophotometric binding assay (K_i) as previously described [4]. Compound **21** ($K_i = 48 \mu\text{M}$) and **23** ($K_i = 70 \mu\text{M}$) showed the highest activity, while compounds **16** (340 μM) and **18** (240 μM) were comparatively less active. Surprisingly, compounds **30** and **47**, in which the favorable 5'-modifications were combined with a 5-CH₂OH modification of the nucleobase, failed to inhibit the enzyme at the highest concentration tested (2.6 and 2.4 mM, respectively). Clearly, introduction of the 5-hydroxymethyl group jeopardized the binding of 5'-modified analogues to **TMPK_{mt}**.




Figure 2. Comparison of structure and interactions of models of **23** (dark blue) and **47** (light blue) superimposed at the active site of *TMPK_{mt}*. Side chains of selected active site residues are shown in stick representations. Majority of hydrogen atoms were omitted for better clarity. Structures of the enzyme-inhibitor complexes were obtained by flexible docking and refinement of the model ligands into the crystal structure of *TMPK_{mt}* co-crystallized with 5-CH₂OH dUMP (PDB entry code 1MRS [5]). For method details see ref. [6].

Discussion and Conclusions

In short, a small series of 5'-modified thymidine analogues was synthesized and evaluated as *TMPK_{mt}* inhibitors. The analogues in which the 5'-hydroxyl group was replaced by an acetonitrile or a 5'-tetrazolylmethyl moiety proved capable of inhibiting the target enzyme with substantial affinity.

Hence we developed a synthetic route that allowed combining these 5'-modifications with a hydroxymethyl moiety at position 5 of the pyrimidine base. Given the recent interest in the phenomenon of hydroxymethylation of pyrimidine bases in mammalian genomes, the successful synthetic strategy, featuring pivaloyl protection of the 5-CH₂OH group prior to 5'-modification, may find future application in the synthesis of other 5-hydroxymethyl-2'-deoxyuridine tool compounds.

It is rather unfortunate that enzyme assays indicated that combination of both modifications did not reinforce the *TMPK_{mt}* binding affinity and led to very weak inhibitors. A possible explanation of the observed drop in the inhibitory potencies of the 5-CH₂OH substituted compounds may be related to an elevated steric strain in the bisubstituted analogs. A superposition of the models of inhibitors **23** and **47** at the active site of *TMPK_{mt}* (Fig.2) shows that the 5'-tetrazolylmethyl moiety is firmly anchored in a polar cavity formed by the charged residues Asp9, Arg160, Asp163, and Glu166 and coordinated by the Mg²⁺ ion and a structural water molecule. However, the thymidine ring shows a higher degree of deviation

between the two inhibitors, while the 5-CH₂OH group of **47** does not seem to reach up to an ideal stabilizing position. As shown on Figure 2, the oxygen of the 5-CH₂OH group is oriented mainly by the interactions with the Arg74 and Phe70 residues into a position where it directs its H atom towards the hydrogen of C_β of Phe36 with a relatively short distance of only 1.85 Å (red line in Fig. 2). This leads to an electrostatic repulsion, which may be responsible for the observed weak inhibitory potency of **47**. In the crystal structure of *TMPK_{mt}* co-crystallized with 5-CH₂OH dUMP [5] the 5-hydroxymethyl group of dUMP is stabilized by hydrogen bonding interactions with the guanidine group of Arg74 and nitrogen atom of Pro37. Still, this does not exclude that a 2',3'-α- fused cyclic sulfuryldiamide substituent may show synergistic inhibitory effects with a 5-CH₂OH group, since conformational restriction by a fused ring may very well change the topology of the molecular interactions with the enzyme.

Experimental

All reagents were from standard commercial sources and of analytical grade. Dry solvents were obtained directly from commercial sources and stored on molecular sieves. All reactions were carried out under argon atmosphere unless specified otherwise. Precoated Merck silica-gel F254 plates were used for TLC; spots were examined under ultraviolet light at 254 nm and further visualized by sulphuric acid-anisaldehyde spray. Column chromatography was performed on silica gel (200-400 mm, 60 Å). NMR spectra were recorded on a Varian Mercury 300 MHz spectrometer. Chemical shifts are given in ppm (δ), calibrated to the residual solvent signals or TMS. Exact mass measurements were performed on a Waters LCT PremierXETM Time of flight (TOF) mass spectrometer equipped with a standard electrospray ionization (ESI) and modular LockSpray™ interface. Samples were infused in a

CH₃CN/water (1:1 v/v) mixture at 10 mL/min. The microwave reactions were carried out in Milestone MicroSYNTH Advanced Microwave Synthesis Labstation, equipped with 2 X 800 W magnetrons (effective maximum output 1500W pulsed/continuous), an optical fiber temperature sensor, a pressure sensor, under continuous power mode in a closed PTFE vessel. A temperature of 25±3 °C is referred to as 'room temperature, rt' throughout the manuscript. NMR signals of sugar protons and carbons are indicated with a prime, and signals of base protons and carbons are given without a prime.

Diethyl ((N-methylsulfonyl)methyl)phosphonate (9): To a solution of **8** (1.0 g, 9.1 mmol) in anhydrous THF (40.0 mL) at – 78 °C was added n-BuLi (1.6M, 11.5 mL, 18.3 mmol) dropwise under argon atmosphere. The mixture was stirred for an hour at – 78 °C and diethyl chlorophosphate (0.67 mL, 4.6 mmol) was added slowly. The reaction mixture was stirred at 0 °C for an hour. The reaction was stopped by adding sat. NH₄Cl solution (10 mL) followed by extraction with dichloromethane (3 X 50 mL). The combined organic layers were dried over anhyd. Na₂SO₄. The desiccant was filtered off and the filtrate was concentrated. The residue was purified by flash column chromatography (50-80% EtOAc in hexanes) to afford unreacted starting material (450 mg) and product **9** as colourless oil (800 mg, 65 % based on recovered starting material). ¹H NMR (300 MHz, CDCl₃) δppm 1.36 (td, *J* = 7.2, 0.9 Hz, 6H, OCH₂Me), 2.37 (d, *J* = 5.4 Hz, 3H, NMe), 3.60 (d, *J* = 16.2 Hz, 2H, SCH₂P), 4.22 (qt, *J* = 6.9 Hz, 0.9 Hz, 4H, OCH₂Me), 5.26 (q, *J* = 5.1 Hz, NH). ¹³C NMR (75 MHz, CDCl₃) δppm 16.14 (d, *J* = 6 Hz, OCH₂CH₃), 29.59 (NCH₃), 46.90 (d, *J* = 138.5 Hz, PCH₂S), 63.53 (d, *J* = 6.1 Hz, OCH₂CH₃). ³¹P NMR (121 MHz, CDCl₃) δ ppm 13.52. ESI-HRMS for [C₆H₁₆NO₅PS + H]⁺ calcd, 246.0565; found, 246.0548.

1-((2R,4S,5R)-4-((tert-butyldimethylsilyloxy)-5-(hydroxymethyl)tetrahydrofuran-2-yl)-5-methylpyrimidine-2,4(1H,3H)-dione (12): Compound **11** (9.71 g, 20.64 mmoles) and

anhydrous THF (106.4 mL) was placed in a Teflon flask under inert condition and cooled to 0 °C. In a separate polypropylene flask, anhydrous THF (79.8 mL) and anhydrous pyridine (31.9 mL) were placed under inert atmosphere; to this at 0 °C ~70% HF in pyridine (28.7 mL) was added drop wise. The chilled THF-Py-HF.Py mixture was added dropwise to a flask containing compound **11** also at 0 °C and stirred at this temperature for 1 hour. The cold bath was removed and reaction continued at room temperature for 45 minutes. The reaction mixture was poured to an ice-cold solution of NaHCO₃ (100g in 500 mL) with vigorous stirring. The compound was extracted in ethyl acetate (3 X 150 mL), washed with brine and dried over anhyd.Na₂SO₄. The residue after evaporation was subjected to flash column chromatography (20 to 50% EtOAc in hexanes) to obtain compound **12** as white foam (2.615 g, 36 %). ¹H NMR (300 MHz, CDCl₃) δ ppm 0.07 (s, 6H, SiMe₂), 0.88 (s, 9H, tBu), 1.88 (s, 3H, 5-Me), 2.20 (ddd, *J* = 13.25, 6.37, 3.81 Hz, 1H, 2'-H), 2.32 (dt, *J* = 13.40, 6.63 Hz, 1H, 2'-H), 2.98 - 3.13 (m, 1H, 5'-OH), 3.68 - 3.80 (m, 1H, 5'-H), 3.85 - 3.96 (m, 2H, 5' & 4'-H), 4.48 (dt, *J* = 6.44, 3.51 Hz, 1H, 3'-H), 6.16 (t, *J* = 6.74 Hz, 1H, 1'-H), 7.35 - 7.48 (m, 1H, 6-H), 9.31 (brs, 1H, NH). ¹³C NMR (75 MHz, CDCl₃) δ ppm -4.66 (SiMe-C), -4.50 (SiMe-C), 12.69 (5-Me-C), 18.15 (tBu-tC), 25.92 (tBu-C), 40.76 (2'-C), 62.11 (5'-C), 71.81 (3'-C), 86.87 (1'-C), 87.84 (4'-C), 111.13 (5-C), 137.25 (6-C), 150.67 (2-C), 164.26 (4-C). ESI-HRMS for [C₁₆H₂₈N₂O₅Si + H]⁺ calcd, 357.1846; found, 357.1847.

1-((2R,4S,5R)-4-((tert-butyldimethylsilyl)oxy)-5-((E)-2-(methylsulfonyl)vinyl)tetrahydrofuran-2-yl)-5-methylpyrimidine-2,4(1H,3H)-dione (14):

To a solution of Dess-Martin reagent (1.28 g, 3 mmol) in anhydrous dichloromethane (5 mL) at 0 °C under argon atmosphere was added compound **12** (713 mg, 2 mmol) in Dichloromethane (5 mL) and the reaction continued at room temperature. After 4 hours saturated NaHCO₃ solution (10 mL) was added and the product extracted in dichloromethane (3 X 20 mL). The organic layers were combined, washed with brine, dried over

anhyd.Na₂SO₄, filtered. The filtrate was evaporated and dried under high vacuum to give aldehyde **13** as white foamy residue which was used without purification for Horner-Wittig reaction.

In a separate flask, Diethyl ((methylsulfonyl)methyl)phosphonate **6** (553 mg, 2.4 mmol) was dissolved in anhydrous THF (20 mL) under argon atmosphere. The mixture was brought to –78 °C and n-BuLi (1.6M in hexanes, 1.38 mL, 2.2 mmol) was added slowly and stirred for 15 minutes. The solution of the above aldehyde **13** (2 mmol) in anhydrous THF (15 mL) was added dropwise. The flask was kept at –78 °C for 1 h and at room temperature overnight (18h). Water (10 mL) was added and the product extracted in ethyl acetate (3 X 50 mL). The combined organic layers were washed with brine, dried over anhyd.Na₂SO₄, filtered and filtrate was evaporated. The residue was purified by flash column chromatography (20-50 % EtOAc in hexanes) to afford **14** as white solid (175 mg, 20 %). ¹H NMR (300 MHz, CDCl₃) δ ppm 0.03 (s, 3H, SiMe), 0.04 (s, 3H, SiMe), 0.84 (s, 9H, t-Bu), 1.89 (d, *J* = 1.17 Hz, 3H, 5-Me), 2.16 - 2.24 (m, 2H, 2'-H), 2.91 (s, 3H, SO₂Me), 4.25 (dt, *J* = 6.37, 4.87 Hz, 1H, 3'-H), 4.33 - 4.43 (m, 1H, 4'-H), 6.22 (t, *J* = 6.74 Hz, 1H, 1'-H) 6.62 (dd, *J* = 15.08, 1.90 Hz, 1H, 6'-H), 6.93 (dd, *J* = 14.94, 4.10 Hz, 1H, 5'-H), 6.96 (d, *J* = 1.17 Hz, 1H, 6-H), 8.39 (s, 1H, NH). ¹³C NMR (75 MHz, CDCl₃) δ ppm -4.78 (SiMe-C), -4.66 (SiMe-C), 12.64 (5Me-C), 17.90 (tBu-tC), 25.63 (tBuMe-C), 39.46 (2'-C), 42.68 (SO₂Me-C), 74.66 (3'-C), 84.05 (4'-C), 85.56 (1'-C), 111.93 (5-C), 130.75 (6'-C), 135.28 (6-C), 142.90 (5'-C), 150.00 (2-C), 163.14 (4-C). ESI-HRMS for [C₁₈H₃₀N₂O₆SSi + H]⁺ calcd, 431.1672; found, 431.1519.

1-((2R,4S,5R)-4-((tert-butyldimethylsilyl)oxy)-5-(2-

(methylsulfonyl)ethyl)tetrahydrofuran-2-yl)-5-methylpyrimidine-2,4(1H,3H)-dione (15):

To a solution of **14** (175 mg, 0.41 mmol) in ethyl acetate (10.0 mL) was added Pd-C (10% Pd, ~50% H₂O, 100 mg) and stirred with purging H₂ gas through the reaction mixture at room temperature for 4 hours. The catalyst was filtered over celite and filtrate was evaporated. The

residue was dried under high vacuum to afford practically pure compound **15** (175 mg) which was used as such for the next step. ^1H NMR (300 MHz, CDCl_3) δ ppm 0.02 (s, 3H, SiMe), 0.03 (s, 3H, SiMe), 0.83 (s, 9H, tBu), 1.89 (d, $J = 1.17$ Hz, 3H, 5-Me), 1.92 - 2.07 (m, 2H, 5'-H), 2.14 - 2.30 (m, 2H, 2'-H), 2.88 (s, 3H, SO_2Me), 3.04 (ddd, $J = 13.7, 11.1, 5.7$ Hz, 1H, 6'-H), 3.13 - 3.25 (m, 1H, 6'-H), 3.75 (dt, $J = 10.40, 3.88$ Hz, 1H, 4'-H), 4.08 - 4.12 (m, 1H, 3'-H), 6.09 (t, $J = 6.88$ Hz, 1H, 1'-H), 6.99 (d, $J = 1.46$ Hz, 1H, 6-H), 8.08 (brs, 1H, NH). ESI-HRMS for $[\text{C}_{18}\text{H}_{32}\text{N}_2\text{O}_6\text{SSi} + \text{H}]^+$ calcd, 433.1829; found, 433.0574.

1-((2R,4S,5R)-4-hydroxy-5-(2-(methylsulfonyl)ethyl)tetrahydrofuran-2-yl)-5-

methylpyrimidine-2,4(1H,3H)-dione (16): To a solution of compound **15** (175 mg, 0.41 mmol) in anhydrous THF (3.0 mL) was added tetrabutylammonium fluoride (TBAF, 0.14 mL, 0.49 mmol) dropwise. The flask was heated to 40 °C overnight. The volatile materials were evaporated under high vacuum and the residue was purified by flash column chromatography (3% MeOH in CH_2Cl_2). The product was purified further by crystallization/triturating in methanol to afford compound **16** as a colorless needles (25 mg, 20 %). ^1H NMR (300 MHz, $\text{DMSO}-d_6$) δ ppm 1.80 (d, $J = 1.17$ Hz, 3H, 5-Me), 1.87 - 2.00 (m, 1H, 5'-H), 2.00 - 2.15 (m, 2H, 2' & 5'-H), 2.25 (dt, $J = 13.84, 6.99$ Hz, 1H, 2'-H), 3.00 (s, 3H, SO_2Me), 3.19 (t, $J = 8.05$ Hz, 2H, 6'-H), 3.72 (dt, $J = 8.57, 4.36$ Hz, 1H, 4'-H), 4.08 - 4.18 (m, 1H, 3'-H), 5.34 (d, $J = 4.39$ Hz, 1H, 3'-OH), 6.15 (t, $J = 7.03$ Hz, 1H, 1'-H), 7.44 (d, $J = 1.17$ Hz, 1H, 6-H), 11.30 (s, 1H, NH). ^{13}C NMR (75 MHz, $\text{DMSO}-d_6$) δ ppm 12.06 (5-Me-C), 25.78 (5'-C), 38.05 (2'-C), 40.15 (SO_2Me -C), 50.39 (6'-C), 72.84 (3'-C), 83.46 (1'-C), 83.83 (4'-C), 109.97 (5-C), 136.17 (6-C), 150.47 (2-C), 163.68 (4-C). ESI-HRMS for $[\text{C}_{12}\text{H}_{18}\text{N}_2\text{O}_6\text{S} + \text{H}]^+$ calcd, 319.0964; found 319.0963.

(E)-2-((2R,3S,5R)-3-((tert-butyldimethylsilyl)oxy)-5-(5-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)tetrahydrofuran-2-yl)-N-methylethanesulfonamide (17):

compound **12** (100 mg, 0.28 mmol) was reacted in similar fashion as described for **14** to get the aldehyde **13**. In a separate flask, to the solution of diethyl ((N-methylsulfamoyl)methyl)phosphonate **11** (83 mg, 0.36 mmol) in anhydrous THF (3 mL) at -78 °C under inert atmosphere was added n-BuLi (1.6M in hexanes, 0.39 mL, 0.62 mmol) drop wise and stirred for 1 h. A solution of above aldehyde **13** (0.28 mmol) in THF (3 mL) was added and the mixture was kept at -78 °C for 1 h then allowed to stir at room temperature overnight (18 h). Water (5 mL) was added and the reaction mixture was extracted with ethyl acetate (3 X 25 mL). The combined organic layer was washed with brine, dried over anhyd.Na₂SO₄, filtered, and evaporated. The residue was purified by preparative TLC (50% EtOAc in toluene) to obtain **17** as a white foam (60 mg, 48 %). ¹H NMR (300 MHz, CDCl₃): δ 0.10 (s, 3H, SiMe), 0.11 (s, 3H, SiMe), 0.91 (s, 9H, t-BuSi), 1.96 (d, *J* = 1.2 Hz, 3H, 5-Me), 2.23-2.29 (m, 2H, 2'-H), 2.76 (s, 3H, NHMe), 4.28-4.33 (m, 1H, 4'-H), 4.41 (td, *J* = 4.8, 1.2 Hz, 1H, 3'-H), 6.30 (t, *J* = 6.9 Hz, 1H, 1'-H), 6.47 (dd, *J* = 15.3, 1.5 Hz, 1H, 6'-H), 6.82 (dd, *J* = 15.3, 4.5 Hz, 1H, 5'-H), 7.04 (d, *J* = 1.2 Hz, 1H, 6-H) ESI-HRMS for [C₁₈H₃₁N₃O₆SSi + H]⁺ calcd, 446.1781; found, 446.1773.

2-((2R,3S,5R)-3-((tert-butyldimethylsilyl)oxy)-5-(5-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)tetrahydrofuran-2-yl)-N-methylethanesulfonamide (18): To a solution of **17** (60 mg, 0.135 mmol) in 5:1 MeOH-THF (1.5 mL) at 0 °C was added NiCl₂·6H₂O (16 mg, 0.075 mmol) and NaBH₄ (10.2 mg, 0.27 mmol). The reaction mixture was stirred for 1 h at 0 °C and the solvent was evaporated. The residue suspended in ethyl acetate, filtrated over celite, the filtrate was evaporated. The residue obtained was dissolved in THF (1.5 mL) and was added TBAF (80 μL, 0.268 mmol). The reaction mixture was stirred at 40

°C for 1 h. The solvent was evaporated to dryness and the residue was purified by flash column chromatography (3-7% MeOH in CH₂Cl₂) to afford **18** (5 mg, 12 %) as white solid. ¹H NMR (300 MHz, DMSO-*d*₆) δ ppm 1.80 (d, *J* = 0.88 Hz, 3H, 5-Me), 1.91 (td, *J* = 9.15, 4.54 Hz, 1H, 5'-H), 1.96 - 2.10 (m, 2H, 2' & 5'-H), 2.24 (dt, *J* = 13.84, 6.99 Hz, 1H, 2'-H), 2.57 (d, *J* = 4.98 Hz, 3H, N-Me), 3.07 (dt, *J* = 9.81, 5.64 Hz, 2H, 6'-H), 3.73 (dt, *J* = 8.42, 4.43 Hz, 1H, 4'-H), 4.11 (dd, *J* = 6.74, 4.10 Hz, 1H, 3'-H), 5.34 (d, *J* = 4.39 Hz, 1H, 3'-OH), 6.14 (t, *J* = 6.88 Hz, 1H, 1'-H), 6.92 (q, *J* = 4.98 Hz, 1H, MeNH) 7.42 (d, *J* = 1.17 Hz, 1H, 6-H), 11.30 (brs, 1H, NH). ¹³C NMR (75 MHz, DMSO-*d*₆) δ ppm 11.96 (5-Me-C), 27.01 (5'-C), 28.47 (NMe-C), 38.04 (2'-C), 46.01 (6'-C), 72.73 (3'-C), 83.29 (1'-C), 83.62 (4'-C), 109.84 (5-C), 136.00 (6-C), 150.33 (2-C), 163.55 (4-C). ESI-HRMS for [C₁₂H₁₉N₃O₆S + H]⁺ calcd, 334.1073; found, 334.1085.

(E)-3-((2R,3S,5R)-3-((tert-butyldimethylsilyloxy)-5-(5-methyl-2,4-dioxo-3,4-

dihydropyrimidin-1(2H)-yl)tetrahydrofuran-2-yl)acrylonitrile (19)¹⁸: Compound **12** (1.22 g, 3.43 mmol) was reacted in similar fashion as described for **14** to get the aldehyde **13**. In a separate flask, to a solution of cyanomethyltriphenylphosphonium chloride (3.48 g, 10.3 mmol) in anhydrous THF (35 mL) at 0 °C under argon atmosphere was added drop wise *n*-BuLi (1.6M in hexanes, 6.4 mL, 10.3 mmol) and stirred for 30 minutes. To this ylide at 0 °C was added slowly a solution of above aldehyde **13** (3.43 mmol) in anhydrous THF (15 mL) and stirred at room temperature overnight. The reaction was quenched with water (30 mL) and extracted with ethyl acetate (3 X 100 mL). Combined organic layer was washed with brine, dried over anhyd.Na₂SO₄, filtered and evaporated. The residue obtained was purified by flash column chromatography (15-30% EtOAc in hexanes) to afford **19** as a light yellow foam (740.4 mg, 57 %). ¹H NMR (300 MHz, CDCl₃) δ ppm 0.09 (s, 3H, SiMe), 0.10 (s, 3H, SiMe), 0.90 (s, 9H, tBu), 1.96 (d, *J* = 1.17 Hz, 3H, 5-Me), 2.27 - 2.36 (m, 2H, 2'-H), 4.27 - 4.35 (m,

2H, 3'-H and 4'-H), 5.67 (dd, $J = 16.26, 1.61$ Hz, 1H, 6'-H), 6.19 (t, $J = 6.59$ Hz, 1H, 1'-H), 6.80 (dd, $J = 16.11, 4.69$ Hz, 1H, 5'-H), 7.01 (d, $J = 1.17$ Hz, 1H, 6-H), 9.46 (s, 1H, NH). ^{13}C NMR (75 MHz, CDCl_3) δ ppm -4.82 (SiMe-C), -4.63 (SiMe-C), 12.65 (5-Me-C), 17.89 (tBu-tC), 25.63 (tBu-C), 39.79 (2'-C) 74.69 (3'-C), 84.96 (4'-C), 86.14 (1'-C), 101.00 (6'-C), 111.74 (5-C), 116.56 (7'-C), 135.74 (6-C) 149.95 (5'-C), 150.25 (2-C), 163.80 (4-C). ESI-HRMS for $[\text{C}_{18}\text{H}_{27}\text{N}_3\text{O}_4\text{Si} + \text{H}]^+$ calcd, 378.1849; found, 378.1852.

3-((2R,3S,5R)-3-((tert-butyldimethylsilyloxy)-5-(5-methyl-2,4-dioxo-3,4-

dihydropyrimidin-1(2H)-yl)tetrahydrofuran-2-yl)propanenitrile (20): To a solution of **19** (443 mg, 1.18 mmol) in 3:1 anhydrous pyridine-MeOH (2 mL) was added NaBH_4 (45 mg, 1.18 mmol) and the reaction mixture was stirred at 120 °C under inert atmosphere for 4h. The reaction mixture was evaporated and the residue was purified by flash column chromatography (30-50% EtOAc in hexanes) to afford **20** as white foam (240 mg, 54%). ^1H NMR (300 MHz, CDCl_3) δ ppm 0.09 (s, 3H, SiMe), 0.10 (s, 3H, SiMe), 0.90 (s, 9H, t-Bu), 1.84 - 1.93 (m, 1H, 5'-H), 1.95 (d, $J = 1.46$ Hz, 3H, 5-Me), 2.02 - 2.16 (m, 1H, 5'-H), 2.27 (t, $J = 6.44$ Hz, 2H, 2'-H), 2.41 - 2.62 (m, 2H, 6'-H), 3.80 (ddd, $J = 9.30, 5.35, 3.81$ Hz, 1H, 4'-H), 4.12 - 4.20 (m, 1H, 3'-H), 6.08 (t, $J = 6.59$ Hz, 1H, 1'-H), 7.05 (d, $J = 1.17$ Hz, 1H, 6-H), 8.44 (brs, 1H, NH). ^{13}C NMR (75 MHz, CDCl_3) δ ppm -4.81 (SiMe-C), -4.53 (SiMe-C), 12.62 (5-Me-C), 14.22 (6'-C), 17.91 (tBu-tC), 25.68 (tBu-C), 28.94 (5'-C), 40.15 (2'-C), 74.43 (3'-C), 84.04 (4'-C), 85.60 (1'-C), 111.35 (5-C), 119.11 (7'-C), 135.87 (6-C), 149.86 (2-C), 163.32 (6-C). ESI-HRMS for $[\text{C}_{18}\text{H}_{29}\text{N}_3\text{O}_4\text{Si} + \text{H}]^+$ calcd, 380.2006; found, 380.2015.

3-((2R,3S,5R)-3-hydroxy-5-(5-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-

yl)tetrahydrofuran-2-yl)propanenitrile (21): To the stirring solution of compound **20** (100 mg, 0.26 mmol) in anhydrous THF (2 mL) was added tetrabutylammonium fluoride (TBAF,

1M in THF, 0.5 mL, 0.5 mmol) under inert atmosphere and stirred at room temperature for 4h. The reaction mixture was evaporated under vacuum and the residue was purified by flash column chromatography (EtOAc) to afford product **21** as a white solid (53 mg, 76%). ¹H NMR (300 MHz, DMSO-*d*₆) δ ppm 1.80 (d, *J* = 1.17 Hz, 3H, 5-Me), 1.83 - 1.98 (m, 2H, 5'-H), 2.05 (ddd, *J* = 13.55, 6.52, 3.95 Hz, 1H, 2'-H), 2.22 (dt, *J* = 13.77, 6.88 Hz, 1H, 2'-H), 2.52 - 2.62 (m, 2H, 6'-H), 3.63 - 3.74 (m, 1H, 4'-H), 4.04 - 4.17 (m, 1H, 5'-H), 5.34 (d, *J* = 4.39 Hz, 1H, 3'-OH), 6.15 (t, *J* = 6.88 Hz, 1H, 1'-H), 7.44 (d, *J* = 1.17 Hz, 1H, 6-H), 11.30 (brs, 1H, NH). ¹³C NMR (75 MHz, DMSO-*d*₆) δ ppm 11.96 (5-Me-C), 13.20 (6'-C), 28.37 (5'-C), 38.01 (2'-C), 72.50 (3'-C), 83.42 (1'-C), 83.92 (4'-C), 109.75 (5-C), 120.30 (7'-C), 136.13 (6-C), 150.33 (2-C), 163.56 (4-C). ESI-HRMS for [C₁₂H₁₅N₃O₄ - H]⁻ calcd, 264.099; found, 264.0617.

1-((2R,4S,5R)-5-(2-(1H-tetrazol-5-yl)ethyl)-4-((tert-butyl)dimethylsilyloxy)tetrahydrofuran-2-yl)-5-methylpyrimidine-2,4(1H,3H)-dione

(22): Compound **20** (120 mg, 0.32 mmol) was dissolved in anhydrous toluene (5 mL), to this was added dibutyltin oxide (Bu₂SnO, 16 mg) and azidotrimethylsilane (TMSN₃, 158 μL, 1.6 mmol) under argon atmosphere. The reaction vessel was sealed with septum and stirred at 110 °C for 4h. The volatiles were evaporated under reduced pressure and the residue was purified by flash column chromatography (2% AcOH/ EtOAc) to afford **22** as a white foam (43 mg, 32%). ¹H NMR (300 MHz, DMSO-*d*₆) δ ppm 0.00 (s, 6 H, SiMe₂), 0.78 (s, 9 H, t-Bu), 1.73 (d, *J* = 0.88 Hz, 3 H, 5-Me), 1.86 - 2.07 (m, 3 H, 2'-H and 5'-H), 2.21 (dt, *J* = 13.62, 6.96 Hz, 1 H, 2'-H), 2.80 - 2.96 (m, 2 H, 6'-H), 3.61 (dt, *J* = 8.42, 4.43 Hz, 1 H, 4'-H), 4.20 (dt, *J* = 6.59, 4.03 Hz, 1 H, 3'-H), 6.04 (t, *J* = 6.88 Hz, 1 H, 1'-H), 7.33 (d, *J* = 1.17 Hz, 1 H, 6-H), 11.23 (brs, 1 H, NH). ¹³C NMR (75 MHz, DMSO-*d*₆) δ ppm -4.89 (SiMe-C), -4.72 (SiMe-C), 12.10 (5-Me-C), 17.61 (tBu-tC), 19.63 (6'-C), 25.65 (tBu-C), 30.42 (5'-C), 38.60 (2'-C),

74.35 (3'-C), 83.46 (1'-C), 84.44 (4'-C), 109.89 (5-C), 136.21 (6-C), 150.39 (2-C), 155.69 (7'-C) 163.66 (4-C). ESI-HRMS for $[C_{18}H_{30}N_6O_4Si - H]^+$ calcd, 421.2020; found, 421.1249.

1-((2R,4S,5R)-5-(2-(1H-tetrazol-5-yl)ethyl)-4-hydroxytetrahydrofuran-2-yl)-5-

methylpyrimidine-2,4(1H,3H)-dione (23): Compound **22** (40 mg, 0.1 mmol) was dissolved in anhydrous THF (2 mL) and added TBAF (0.5 mL, 0.5 mmol) at room temperature. After 4h, methanol (2 mL) was added, followed by CaCO₃ (1g) with vigorous stirring. After 10 minutes was added Dowex resin (H⁺ form, 1g) portion wise. The mixture was stirred for 30 minutes and filtered over a pad of celite. The filtrate was concentrated and purified by flash column chromatography (5-8 % MeOH + 2% AcOH in CH₂Cl₂) to afford title compound **23** as a white solid (10 mg, 34%). ¹H NMR (300 MHz, DMSO-*d*₆) δ ppm 1.80 (d, *J* = 1.17 Hz, 3 H, 5-Me), 1.89 - 2.14 (m, 3 H, 2'-H and 5'-H), 2.14 - 2.33 (m, 1 H, 2'-H), 2.87 - 3.06 (m, 2 H, 6'-H), 3.66 (dt, *J* = 8.57, 4.36 Hz, 1 H, 4'-H), 4.05 - 4.17 (m, 1 H, 3'-H), 5.30 (brs, 1 H, 3'-OH), 6.14 (t, *J* = 6.88 Hz, 1 H, 1'-H), 7.39 (d, *J* = 0.88 Hz, 1 H, 6-H), 11.30 (s, 1 H, NH). ¹³C NMR (75 MHz, DMSO-*d*₆) δ ppm 11.99 (5-Me-C), 19.39 (6'-C), 30.56 (5'-C), 38.20 (2'-C), 72.73 (3'-C), 83.18 (1'-C), 84.30 (4'-C), 109.79 (5-C), 135.94 (6-C), 150.33 (2-C), 155.07 (7'-C), 163.56 (4-C). ESI-HRMS for $[C_{12}H_{16}N_6O_4 - H]^+$ calcd, 307.1155; found, 307.0597.

1-((2R,4S,5R)-4-((tert-butyldimethylsilyl)oxy)-5-(hydroxymethyl)tetrahydrofuran-2-

yl)pyrimidine-2,4(1H,3H)-dione (26): Removal of primary TBS group using the procedure described for compound **12**, compound **25** (1.8 g, 4 mmol) rendered **26** (600 mg, 53%) as a white solid. ¹H NMR (300 MHz, CDCl₃) δ ppm 0.09 (s, 6H, SiMe), 0.90 (s, 9H, tBu), 2.24 - 2.32 (m, 2H, 2'-H) 2.50 (brs, 1H, 5'-OH), 3.69 - 3.82 (m, 1H, 5'-H), 3.87 - 4.00 (m, 2H, 4'-H and 5'-H), 4.43 - 4.55 (m, 1H, 3'-H), 5.74 (dd, *J* = 8.20, 2.05 Hz, 1H, 5-H), 6.18 (t, *J* = 6.59

Hz, 1H, 1'-H), 7.65 (d, $J = 8.20$ Hz, 1H, 6-H), 8.89 (brs, 1H, NH). ^{13}C NMR (75 MHz, CDCl_3) δ ppm -4.64 (SiMe-C), -4.47 (SiMe-C), 18.18 (tBu-tC), 25.93 (tBu-C), 41.09 (2'-C), 62.09 (5'-C), 71.64 (3'-C), 87.02 (1'-C), 87.82 (4'-C), 102.71 (5-C), 141.31 (6-C), 150.42 (2-C), 163.40 (4-C). ESI-HRMS for $[\text{C}_{15}\text{H}_{26}\text{N}_2\text{O}_5\text{Si} + \text{H}]^+$ calcd, 343.1689; found, 343.1682.

(E)-3-((2R,3S,5R)-3-((tert-butyldimethylsilyl)oxy)-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)tetrahydrofuran-2-yl)acrylonitrile (27): Following the oxidation and Wittig reaction procedure described for compound **19**, compound **26** (600 mg, 1.75 mmol) rendered **27** (325 mg, 51%) as a white solid. ^1H NMR (300 MHz, CDCl_3) δ ppm 0.10 (s, 6H, SiMe₂), 0.90 (s, 9H, tBu), 2.19 - 2.43 (m, 2H, 2'-H), 4.24 - 4.30 (m, 1H, 3'-H), 4.30 - 4.37 (m, 1H, 4'-H), 5.67 (dd, $J = 16.40, 1.76$ Hz, 1H, 6'-H), 5.81 (dd, $J = 8.20, 2.34$ Hz, 1H, 5-H), 6.19 (t, $J = 6.44$ Hz, 1H, 1'-H), 6.77 (dd, $J = 16.11, 4.69$ Hz, 1H, 5'-H), 7.21 (d, $J = 8.20$ Hz, 1H, 6-H), 8.65 (brs, 1H, NH). ^{13}C NMR (75 MHz, CDCl_3) δ ppm -4.82 (SiMe-C), -4.63 (SiMe-C), 17.90 (tBu-tC), 25.63 (tBu-C), 40.06 (2'-C), 74.59 (3'-C), 85.04 (4'-C), 86.30 (1'-C), 101.19 (6'-C), 103.21 (5-C), 116.42 (7'-C), 139.83 (6-C), 149.61 (5'-C), 149.82 (2-C), 162.71 (4-C). ESI-HRMS for $[\text{C}_{17}\text{H}_{25}\text{N}_3\text{O}_4\text{Si} + \text{CH}_3\text{CN} + \text{H}]^+$ calcd, 405.1958; found, 405.1955.

3-((2R,3S,5R)-3-((tert-butyldimethylsilyl)oxy)-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)tetrahydrofuran-2-yl)propanenitrile (28): Following the reaction procedure described for compound **15** but using methanol as solvent, compound **27** (55 mg, 0.15 mmol) gave **28** as a white solid (50 mg, 89%). ^1H NMR (300 MHz, CDCl_3) δ ppm 0.09 (d, 6H, SiMe₂), 0.90 (s, 9H, tBu), 1.89 (dddd, $J = 13.84, 9.45, 7.47, 6.15$ Hz, 1H, 5'-H), 2.03 - 2.15 (m, 1H, 5'-H), 2.19 - 2.38 (m, 2H, 2'-H), 2.42 - 2.62 (m, 2H, 6'-H), 3.82 (ddd, $J = 9.37, 5.42, 3.66$ Hz, 1H, 4'-H), 4.14 (dt, $J = 7.03, 5.42$ Hz, 1H, 3'-H), 5.77 (d, $J = 7.91$ Hz, 1H, 5-H), 6.08 (t, $J = 6.59$

Hz, 1H, 1'-H), 7.26 (d, $J = 8.20$ Hz, 1H, 6-H), 8.40 (brs, 1H, NH). ^{13}C NMR (75 MHz, CDCl_3) δ ppm -4.83 (SiMe-C), -4.54 (SiMe-C), 14.25 (6'-C), 17.90 (tBu-tC), 25.67 (tBu-C), 28.98 (5'-C), 40.40 (2'-C), 74.37 (3'-C), 84.20 (4'-C), 85.95 (1'-C), 102.83 (5-C), 119.01 (7'-C), 140.08 (6-C), 149.84 (2-C), 162.84 (4-C). ESI-HRMS for $[\text{C}_{17}\text{H}_{27}\text{N}_3\text{O}_4\text{Si} + \text{H}]^+$ calcd, 366.1849; found, 366.1842.

3-((2R,3S,5R)-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-3-hydroxytetrahydrofuran-2-yl)propanenitrile (29): Following the reaction procedure described for compound **21**, compound **28** (50 mg, 0.14 mmol) rendered **29** (25 mg, 73%) as a white solid. ^1H NMR (300 MHz, CD_3OD) δ ppm 1.89 - 2.14 (m, 2H, 5'-H), 2.20 - 2.37 (m, 2H, 2'-H), 2.48 - 2.69 (m, 2H, 6'-H), 3.85 (dt, $J = 9.23, 4.47$ Hz, 1H, 4'-H), 4.13 - 4.25 (m, 1H, 3'-H), 5.71 (d, $J = 7.91$ Hz, 1H, 5-H), 6.18 (t, $J = 6.74$ Hz, 1H, 1'-H), 7.62 (d, $J = 8.20$ Hz, 1H, 6-H). ^{13}C NMR (75 MHz, CD_3OD) δ ppm 14.48 (6'-C), 30.32 (5'-C), 40.21 (2'-C), 74.68 (3'-C), 85.87 (4'-C), 86.71 (1'-C), 103.04 (5-C), 120.79 (7'-C), 142.57 (6-C), 152.07 (2-C), 166.15 (4-C). ESI-HRMS for $[\text{C}_{11}\text{H}_{13}\text{N}_3\text{O}_4 - \text{H}]^-$ calcd, 250.0828; found, 250.0833.

(1-((2R,4S,5R)-4-((tert-butyldimethylsilyl)oxy)-5-(hydroxymethyl)tetrahydrofuran-2-yl)-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-5-yl)methyl acetate (32): Following the procedure described for the synthesis of **12**, compound **31** (1 g, 1.94 mmol) rendered **32** (265 mg, 33%) as a white foam. ^1H NMR (300 MHz, CDCl_3) δ ppm 0.09 (s, 6H, SiMe), 0.90 (s, 9H, tBu), 2.06 (s, 3H, OAc), 2.18 - 2.40 (m, 2H, 2'-H), 3.77 (dd, $J = 12.7, 3.2$ Hz, 1H, 5'-H), 3.88 - 4.04 (m, 2H, 5' & 4'-H), 4.52 (dt, $J = 5.80, 3.70$ Hz, 1H, 3'-H), 4.79 - 4.97 (m, 2H, 5- CH_2O), 6.24 (t, $J = 6.49$ Hz, 1H, 1'-H), 8.11 (s, 1H, 6-H), 9.02 (s, 1H, NH). ^{13}C NMR (75 MHz, CDCl_3) δ ppm -4.90, -4.74 (SiMe-C), 17.94 (tBu-tC), 21.14 (Ac-C), 25.69 (tBu-C), 41.36 (1'-C), 58.82

(5-CH₂O-C), 61.82 (5'-C), 71.66 (3'-C), 86.49 (1'-C), 88.12 (4'-C), 109.02 (5-C), 142.86 (6-C), 149.94 (2-C), 162.58 (4-C), 171.96 (Ac-C=O). ESI-HRMS for [C₁₈H₃₀N₂O₇Si + H]⁺ calcd, 415.1901; found, 415.1904.

5-(((benzyloxy)methoxy)methyl)-3-(((benzyloxy)methyl)-1-((2R,4S,5R)-4-((tert-butyl)dimethylsilyloxy)-5-(((tert-butyl)dimethylsilyloxy)methyl)tetrahydrofuran-2-yl)pyrimidine-2,4(1H,3H)-dione (34): To a mixture of compound **33** (150 mg, 0.31 mmol) in anhydrous DMF (2.5 mL) and anhydrous diisopropylethylamine (DIPEA, 160 μL, 0.92 mmol) at 0 °C under inert atmosphere was added drop wise benzyloxymethyl chloride (~75 % BOMCl, 94 μL, 0.68 mmol) and stirred at room temperature overnight. Saturated aq.NH₄Cl (5 mL) was added to quench the reaction. The products were extracted in ethyl acetate (50 mL), organic layer washed with water, brine, dried over anhyd.Na₂SO₄ and evaporated. The residue was purified by flash column chromatography (5-10 % EtOAc in hexanes) to yield **34** (80 mg, 36 %). ¹H NMR (300 MHz, CDCl₃) δ ppm 0.08 - 0.12 (m, 12H, SiMe), 0.88 - 0.94 (m, 18H, tBu), 1.97 (ddd, *J* = 13.34, 7.64, 5.97 Hz, 1H, 2'-H), 2.30 (ddd, *J* = 13.16, 5.74, 2.44 Hz, 1H, 2'-H), 3.76 (dd, *J* = 11.40, 3.08 Hz, 1H, 5'-H), 3.82 (dd, *J* = 11.22, 3.26 Hz, 1H, 5'-H), 3.96 (q, *J* = 3.08 Hz, 1H, 4'-H), 4.34 - 4.47 (m, 3H, 3'-H & 5-CH₂), 4.65 (s, 2H, OCH₂Ph), 4.71 (s, 2H, OCH₂Ph), 4.80 - 4.87 (m, 2H, OCH₂O), 5.50 (s, 2H, NCH₂O), 6.31 (dd, *J* = 7.87, 5.70 Hz, 1H, 1'-H), 7.22 - 7.41 (m, 10H, Ar), 7.65 (s, 1H, 6-H). ¹³C NMR (75 MHz, CDCl₃) δ ppm -5.50, -5.40, -4.84, -4.65 (SiMe-C), 17.98, 18.39 (tBu-tC), 25.73, 25.93 (tBu-C), 41.35 (1'-C), 62.99 (5-CH₂-C), 63.07 (5'-C), 69.39 (Bn-C), 70.45 (NCH₂O-C), 72.24 (3'-C), 72.28 (Bn-C), 85.95 (1'-C), 87.94 (4'-C), 94.36 (OCH₂O-C), 110.72 (5-C) 126.97, 127.61, 127.69, 127.92, 128.26, 128.39, 128.56 (Ar-C), 136.92 (6-C), 137.70, 137.93 (Ar-C), 150.80 (2-C), 162.24 (4-C). ESI-HRMS for [C₃₈H₅₈N₂O₈Si₂ + H]⁺ calcd, 727.381; found, 727.3805.

1-((2R,4S,5R)-4-((tert-butyldimethylsilyl)oxy)-5-(((tert-butyldimethylsilyl)oxy)methyl)tetrahydrofuran-2-yl)-5-(((2-(trimethylsilyl)ethoxy)methoxy)methyl)-3-((2-(trimethylsilyl)ethoxy)methyl)pyrimidine-2,4(1H,3H)-dione (35): Under an inert condition compound **33** (486 mg, 1 mmol) was dissolved in anhydrous CH₂Cl₂ (3 mL) and anhydrous DIPEA (0.5 mL, 3 mmol) and added ethyltrimethylsilylchloromethyl ether (SEMCl, 0.44 ml, 2.5 mmol). The reaction was continued at 40 °C for 6h. The reaction mixture was partitioned between brine (5 mL) and ethyl acetate (20 mL). The organic layer was separated and dried over anhyd.Na₂SO₄. The residue after evaporation of organic phase was purified by flash column chromatography (5% EtOAc in hexanes) to afford compound **35** (370 mg, 50 %) as a glass. ¹H NMR (300 MHz, CDCl₃) δ ppm 0.00 (s, 9H, SiMe₃-SEM), 0.03 (s, 9H, SiMe₃-SEM), 0.08 (s, 3H, SiMe-TBS), 0.09 (s, 3H, SiMe-TBS), 0.11 (s, 6H, SiMe₂-TBS), 0.90 (s, 9H, tBu), 0.92 (s, 9H, tBu), 0.94-1.02 (m, 4H, Me₃SiCH₂), 2.00 (ddd, *J* = 15.3 Hz, 7.8 Hz, 1.8 Hz, 1H, 2'-H), 2.31 (ddd, *J* = 13.2 Hz, 5.7 Hz, 2.4 Hz, 1H, 2'-H), 3.60-3.73 (m, 4H, OCH₂CH₂SiMe₃), 3.76 (dd, *J* = 11.10, 3.15 Hz, 1H, 5'-H), 3.82 (dd, *J* = 11.29, 3.33 Hz, 1H, 5'-H), 3.96 (q, *J* = 2.96 Hz, 1H, 4'-H), 4.31 (d, *J* = 12.24 Hz, 1H, 5-CH₂), 4.37 (d, *J* = 12.0 Hz, 1H, 5-CH₂), 4.37-4.42 (m, 1H, 3'-H), 4.74 (s, 2H, OCH₂O), 5.40 (s, 2H, NCH₂O), 6.32 (1H, dd, *J* = 7.8 Hz, 5.7 Hz, 1'-H), 7.65 (s, 1H, 6-H). ¹³C NMR (75 MHz, CDCl₃): δ ppm -5.50, -5.38, -4.84, -4.67 (TBSSiMe -C), -1.44, -1.38 (SEMSiMe₃-C), 17.97 (t-Bu-tC), 18.07, 18.11 (SEMSiCH₂-C); 18.40 (t-Bu-tC), 25.72, 25.95 (tBu-C), 41.34 (2'-C), 62.96 (5-CH₂O-C), 62.99 (5'-C), 65.28, 67.49 (SEMCH₂O-C), 70.22 (NCH₂O-C), 72.43 (3'-C), 86.11 (1'-C), 88.06 (4'-C), 94.94 (OCH₂O-C), 111.08 (5-C), 136.71 (6-C), 150.99 (2-C), 162.34 (4-C). ESI-HRMS for [C₃₄H₇₀N₂O₈Si₄ + H]⁺ calcd, 747.4287; found, 747.4144.

1-((2R,4S,5R)-4-((tert-butyldimethylsilyl)oxy)-5-(hydroxymethyl)tetrahydrofuran-2-yl)-5-(((2-(trimethylsilyl)ethoxy)methoxy)methyl)-3-((2-(trimethylsilyl)ethoxy)methyl)pyrimidine-2,4(1H,3H)-dione (36): Following the procedure described for the synthesis of **12**, compound **35** (350 mg, 0.48 mmol) gave compound **36** as a glass (114 mg, 38 %). ¹H NMR (300 MHz, CDCl₃) δ ppm 0.00 (s, 9H, SiMe₃-SEM), 0.03 (s, 9H, SiMe₃-SEM), 0.09 (s, 6H, SiMe-TBS), 0.90 (s, 9H, tBu); 0.92-1.00 (m, 4H, SEMSiCH₂), 2.22-2.41 (m, 2H, 2'-H), 2.58 (t, *J* = 4.8 Hz, 1H, 5'-OH), 3.60-3.72 (m, 4H, SEMCH₂O), 3.72-3.80 (m, 1H, 5'-H), 3.87-3.93 (m, 1H, 5'-H), 3.93-3.98 (m, 1H, 4'-H), 4.39 (s, 2H, 5-CH₂O), 4.51 (1H, dt, *J* = 6.6, 3.81 Hz, 3'-H), 4.73 (s, 2H, OCH₂O), 5.39 (s, 2H, NCH₂O), 6.20 (t, *J* = 6.44 Hz, 1H, 1'-H), 7.75 (s, 1H, 6-H). ¹³C NMR (75 MHz, CDCl₃) δ ppm -4.86, -4.69 (TBSSiMe-C), -1.43, -1.42 (SEMSiMe₃-C), 17.95 (tBu-tC), 18.12 (SEMSiCH₂-C), 25.71 (tBu-C), 40.91 (2'-C), 62.04 (5'-C), 62.27 (5-CH₂O-C), 65.56, 67.58 (SEMCH₂O-C), 70.03 (NCH₂O-C), 71.68 (3'-C), 87.80 (1'-C), 87.88 (4'-C), 93.96 (OCH₂O-C), 110.24 (5-C), 138.05 (6-C), 150.86 (2-C), 162.03 (4-C). ESI-HRMS for [C₂₈H₅₆N₂O₈Si₃ + H]⁺ calcd, 633.3423; found, 633.3451.

1-((2R,4S,5R)-4-((tert-butyldimethylsilyl)oxy)-5-((E)-2-(methylsulfonyl)vinyl)tetrahydrofuran-2-yl)-5-(((2-(trimethylsilyl)ethoxy)methoxy)methyl)-3-((2-(trimethylsilyl)ethoxy)methyl)pyrimidine-2,4(1H,3H)-dione (37): Following the procedure described for the synthesis of **14**, compound **36** (113 mg, 0.18 mmol) rendered **37** as white solid (33 mg, 29 %). ¹H NMR (300 MHz, CDCl₃) δ ppm 0.00 (s, 9H, SEM SiMe₃), 0.02 (s, 9H, SEM SiMe₃), 0.10 (s, 3H, TBSSiMe), 0.10 (s, 3H, TBSSiMe), 0.90 (s, 9H, tBu), 0.92-1.02 (s, 4H, SEMSiCH₂), 2.15-2.40 (m, 2H, 2'-C), 2.97 (s, 3H, SO₂Me), 3.58-3.75 (m, 4H, SEMCH₂O), 4.33 (dt, *J* = 6.4, 4.7 Hz, 1H, 4'-H), 4.40 (s, 2H, 5-CH₂O), 4.47 (td, *J* = 4.7, 1.8 Hz, 1H, 3'-H), 4.73 (s, 2H, OCH₂O), 5.39 (s, 2H, NCH₂O), 6.33 (t, *J* = 6.6 Hz, 1H, 1'-H), 6.69 (dd, *J* = 15.3 Hz, 1.8 Hz, 1H, 6'-H), 7.00

(1H, dd, $J = 15$ Hz, 4.2 Hz, 5'-H), 7.34 (s, 1H, 6-H). ESI-HRMS for $[C_{30}H_{58}N_2O_9SSi_3 + Na]^+$ calcd, 729.3069; found, 729.1077.

1-((2R,4S,5R)-4-((tert-butyldimethylsilyl)oxy)-5-(((tert-butyldimethylsilyl)oxy)methyl)tetrahydrofuran-2-yl)-3-(4-methoxybenzyl)-5-(((4-methoxybenzyl)oxy)methyl)pyrimidine-2,4(1H,3H)-dione (38): To a stirring solution of **33** (200 mg, 0.41 mmol) in anhydrous DMF (2 mL) at 0 °C under argon atmosphere was added 4-methoxybenzyl chloride (PMBCl, 167 μ L, 1.23 mmol) followed by NaH (60% in mineral oil, 50 mg, 1.23 mmol) portion wise and stirred at room temperature for 4h. Ethyl acetate (20 mL) and saturated aq.NH₄Cl (10 mL) was added. The aqueous layer was extracted with ethyl acetate (3 X 20 mL) and the combined organic layers were dried over anhyd.Na₂SO₄, filtered, evaporated. The residue was purified by flash column chromatography (10% EtOAc in hexanes) to afford the title compound **38** as a white foam (40 mg, 13%). ¹H NMR (300 MHz, CDCl₃) δ ppm 0.05 (s, 3H, SiMe), 0.06 (s, 6H, SiMe), 0.07 (s, 3H, SiMe), 0.88 (s, 9H, tBu), 0.89 (s, 9H, tBu), 1.97 (ddd, $J = 13.40, 7.69, 6.15$ Hz, 1H, 2'-H), 2.26 (ddd, $J = 13.18, 5.71, 2.49$ Hz, 1H, 2'-H), 3.72 - 3.76 (m, 1H, 5'-H), 3.77 (s, 3H, PMB-OMe), 3.79 (s, 2H, PMB-OMe), 3.92 (q, $J = 3.22$ Hz, 1H, 5'-H), 4.18 - 4.33 (m, 2H, 5-CH₂O,) 4.37 (dt, $J = 5.64, 2.60$ Hz, 1H, 3'-H), 4.52 (s, 2H, PMB OCH₂), 4.95 - 5.13 (m, 2H, PMB NCH₂), 6.32 (dd, $J = 7.91, 5.56$ Hz, 1H, 1'-H), 6.82 (d, $J = 8.79$ Hz, 2H, Ar), 6.86 (d, $J = 8.49$ Hz, 2H, Ar), 7.26 (d, $J = 8.49$ Hz, 2H, Ar), 7.44 (d, $J = 8.79$ Hz, 2H, Ar), 7.59 (s, 1H, 6-H). ¹³C NMR (75 MHz, CDCl₃) δ ppm -5.51, -5.43, -4.84, -4.66 (SiMe-C), 17.98, 18.39 (tBu-tC), 25.74, 25.94 (tBu-C), 41.17 (2'-C), 43.88 (NCH₂-C), 55.23, 55.25 (OMe-C), 63.01 (5'-C), 65.06 (5-CH₂O-C), 72.30 (3'-C), 72.81 (PMBCH₂O-C), 85.83 (1'-C), 87.80 (4'-C), 111.19 (5-C), 113.69, 113.80, 129.05, 129.51, 130.06, 130.73 (Ar-C) 135.99 (6-C), 150.80 (2-C), 159.04, 159.27 (Ar-C), 162.23 (2-C). ESI-HRMS for $[C_{38}H_{58}N_2O_8Si_2 + H]^+$ calcd, 727.3810; found, 727.3797.

(1-((2R,4S,5R)-4-((tert-butyldimethylsilyl)oxy)-5-(((tert-butyldimethylsilyl)oxy)methyl)tetrahydrofuran-2-yl)-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-5-yl)methyl pivalate (39): To a solution of **33** (2.0 g, 4.1 mmol) in anhydrous pyridine (20 mL) and DMAP (100 mg) under inert atmosphere was added pivaloyl chloride (0.76 mL, 6.16 mmol) and the reaction mixture was stirred at room temperature overnight (18h). Pyridine was evaporated under reduced pressure and the residue was purified by flash column chromatography (10-25 % EtOAc in hexanes) to afford **39** as a white solid (2.0g, 74 %). ¹H NMR (300 MHz, CDCl₃) δ ppm 0.09 (s, 3H, SiMe), 0.09 (s, 2H, SiMe), 0.10 (s, 6H, SiMe₂), 0.90 (d, 9H, Si-tBu), 0.91 (d, 9H, Si-tBu), 1.19 (s, 9H, Piv-tBu), 2.01 (ddd, *J* = 13.40, 7.69, 5.86 Hz, 1H, 2'-H), 2.32 (ddd, *J* = 13.18, 5.86, 2.64 Hz, 1H, 2'-H), 3.73 - 3.85 (m, 2H, 5'-H), 3.96 (q, *J* = 3.22 Hz, 1H, 4'-H), 4.40 (dt, *J* = 5.49, 2.67 Hz, 1H, 3'-H), 4.80 (s, 2H, 5-CH₂), 6.28 (dd, *J* = 7.91, 5.86 Hz, 1H, 1'-H), 7.78 (s, 1H, 6-H), 8.28 (s, 1H, NH). ¹³C NMR (75 MHz, CDCl₃) δ ppm -5.42 (SiMe-C), -5.38 (SiMe-C), -4.83 (SiMe-C), -4.65 (SiMe-C), 18.01 (Si-tBu-tC), 18.42 (Si-tBu-tC), 25.74 (Si-tBu-C), 25.93 (Si-tBu-C), 27.15 (Piv-tBu-C), 38.79 (Piv-tBu-tC), 41.39 (2'-C), 59.07 (5-CH₂-C), 63.11 (5'-C), 72.36 (3'-C), 85.51 (1'-C), 88.09 (4'-C), 109.62 (5-C), 140.25 (6-C), 149.76 (2-C), 161.86 (4-C), 178.23 (Piv-C=O-C). ESI-HRMS for [C₂₇H₅₀N₂O₇Si₂ + H]⁺ calcd, 571.3235; found, 471.3242.

(1-((2R,4S,5R)-4-((tert-butyldimethylsilyl)oxy)-5-(hydroxymethyl)tetrahydrofuran-2-yl)-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-5-yl)methyl pivalate (40): Following the procedure described for the synthesis of **12**, compound **39** (2.0 g, 3.05 mmol) gave compound **40** as a white solid (822 mg, 59 %). ¹H NMR (300 MHz, CDCl₃) δ ppm 0.09 (s, 6H, SiMe), 0.90 (s, 9H, TBS-tBu), 1.18 (s, 9H, Piv-tBu), 2.19 - 2.38 (m, 2H, 2'-H), 2.94 (t, *J* = 5.32 Hz, 1H, 5'-

OH), 3.70 - 3.81 (m, 1H, 5'-H), 3.90 - 3.99 (m, 2H, 5' & 4'-H), 4.52 (dt, $J = 6.25, 3.54$ Hz, 1H, 3'-H), 4.83 - 4.94 (m, 2H, 5-CH₂O), 6.23 (t, $J = 6.67$ Hz, 1H, 1'-H), 8.08 (s, 1H, 6-H), 8.78 (s, 1H, NH). ¹³C NMR (75 MHz, CDCl₃) δ ppm -4.86, -4.70 (SiMe-C), 17.98 (TBS tBu-tC), 25.73 (tBu-C), 27.04 (tBu-C), 38.97 (piv tBu-tC), 41.42 (2'-C), 58.63 (5-CH₂O-C), 62.06 (5'-C), 71.91 (3'-C), 86.60 (1'-C), 88.29 (4'-C), 109.26 (5-C), 142.71 (6-C), 149.70 (2-C), 161.95 (4-C), 179.70 (PivCO-C). ESI-HRMS for [C₂₁H₃₆N₂O₇Si + H]⁺ calcd, 457.2370; found, 457.2414.

(1-((2R,4S,5R)-4-((tert-butyldimethylsilyl)oxy)-5-(2-cyanovinyl)tetrahydrofuran-2-yl)-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-5-yl)methyl pivalate (41): Following the similar procedure to synthesize **13**, the reaction of compound **40** (0.8 g, 1.75 mmol), Dess-Martin reagent (0.48 M in CH₂Cl₂, 4.4 mL, 2.1 mmol) at room temperature for 7h gave aldehyde as white foamy residue.

In a separate flask, to a solution of cyanomethyltriphenylphosphonium chloride (1.78 g, 5.25 mmol) in anhydrous THF (30 mL) at -78 °C under argon condition was added drop wise n-BuLi (1.6M in hexanes, 3.3 mL, 5.25 mmol) and stirred for 30 minutes. To this ylide at -78 °C was added slowly a solution of above aldehyde in anhydrous THF (5 mL) and stirred at room temperature overnight. Following the similar workup procedure described for compound **19**, afforded **41** as a white solid (E-isomer - 450 mg and E+Z mixture - 240 mg, 82%). Data for E-isomer: ¹H NMR (300 MHz, CDCl₃) δ ppm 0.10 (s, 3H, SiMe), 0.11 (s, 3H, SiMe), 0.90 (s, 9H, TBS tBu), 1.20 (s, 9H, Piv tBu), 2.21 - 2.42 (m, 2H, 2'-H), 4.25 - 4.38 (m, 2H, 3' & 4'-H), 4.81 - 4.95 (m, 2H, 5-CH₂O), 5.72 (dd, $J = 16.40, 1.76$ Hz, 1H, 6'-H), 6.24 (t, $J = 6.44$ Hz, 1H, 1'-H), 6.79 (dd, $J = 16.26, 4.54$ Hz, 1H, 5'-H), 7.54 (s, 1H, 6-H), 9.34 (brs, 1H, NH). ¹³C NMR (75 MHz, CDCl₃) δ ppm -4.84, -4.66 (SiMe-C), 17.89 (TBS tBu-tC),

25.63 (tBu-C), 27.12 (tBu-C), 38.91 (Piv tBu-tC), 40.10 (2'-C), 58.36 (5-CH₂O-C), 74.53 (3'-C), 85.12 (4'-C), 86.07 (1'-C), 101.41 (6'-C), 110.38 (7'-C), 116.49 (5-C), 140.93 (6-C), 149.39 (5'-C), 149.70 (2-C), 162.32 (4-C), 178.84 (Piv CO-C). ESI-HRMS for [C₂₃H₃₅N₃O₆Si + H]⁺ calcd, 478.2373; found, 478.2383.

(1-((2R,4S)-5-(2-cyanoethylidene)-4-hydroxytetrahydrofuran-2-yl)-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-5-yl)methyl pivalate (42): To a solution of compound **41** (65 mg, 0.136 mmol) in THF (1 mL) was added tetrabutylammonium hydroxide (Bu₄N⁺OH⁻, 40% in H₂O, 186 mg, 0.286 mmol) and stirred at room temperature for 5h. Volatiles were evaporated under reduced pressure and the residue was purified by flash column chromatography (40-70% EtOAc in hexanes) to afford **42** as a white powder (20 mg, 40%). ¹H NMR (300 MHz, CDCl₃) δ ppm 1.19 (s, 9H, tBu), 2.20 (d, *J* = 3.51 Hz, 1H, 3'-OH), 2.31 (dt, *J* = 13.84, 6.70 Hz, 1H, 2'-H), 2.56 (ddd, *J* = 14.06, 6.44, 2.64 Hz, 1H, 2'-H), 3.17 (dd, *J* = 7.03, 1.17 Hz, 2H, 6'-H), 4.77 (t, *J* = 7.03 Hz, 1H, 5'-H), 4.83 - 4.92 (m, 3H, 3'-H & 5-CH₂O-H), 6.62 (t, *J* = 6.74 Hz, 1H, 1'-H), 7.38 (s, 1H, 6-H), 8.46 (s, 1H, NH). ¹³C NMR (75 MHz, CDCl₃) δ ppm 13.70 (6-C), 27.10 (tBu-C) 38.90 (tBu-tC), 39.22 (2'-C), 58.48 (5-CH₂O-C), 70.25 (3'-C), 87.13 (1'-C), 89.96 (5'-C), 111.06 (5-C), 117.77 (7'-C), 139.55 (6-C), 149.40 (2-C), 159.39 (4-C), 161.42 (4'-C), 178.68 (Piv CO-C). ESI-HRMS for [C₁₇H₂₁N₃O₆ + H]⁺ calcd, 364.1509; found, 364.1455.

(1-((2R,4S,5R)-4-((tert-butyldimethylsilyl)oxy)-5-(2-cyanoethyl)tetrahydrofuran-2-yl)-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-5-yl)methyl pivalate (43): To a solution of **41** (240 mg, 0.5 mmol) in ethylacetate (10 mL) was added 5%Pt-C (250 mg) and stream of hydrogen gas was bubbled through the reaction mixture for 4h. The catalyst was filtered off and the

filtrate was concentrated. The residue was purified by flash column chromatography (20-40% EtOAc in hexanes) to afford **43** as a white solid (170 mg, 70%). ¹H NMR (300 MHz, CDCl₃) δ ppm 0.09 (s, 3H, SiMe), 0.10 (s, 3H, SiMe), 0.90 (s, 9H, TBS tBu), 1.20 (s, 9H, Piv tBu), 1.94 (dddd, *J* = 13.88, 9.63, 7.54, 6.15 Hz, 1H, 5'-H), 2.02 - 2.17 (m, 1H, 5'-H), 2.23 (ddd, *J* = 13.40, 7.25, 5.71 Hz, 1H, 2'-H), 2.34 (ddd, *J* = 13.77, 7.03, 5.86 Hz, 1H, 2'-H), 2.43 - 2.65 (m, 2H, 6'-H), 3.85 (ddd, *J* = 9.37, 5.42, 3.66 Hz, 1H, 4'-H), 4.16 (dt, *J* = 11.13, 5.57 Hz, 1H, 3'-H), 4.88 (s, 2H, 5-CH₂O), 6.12 (dd, *J* = 6.74, 5.86 Hz, 1H, 1'-H), 7.55 (s, 1H, 6'-H), 9.13 (brs, 1H, NH). ¹³C NMR (75 MHz, CDCl₃) δ ppm -4.88, -4.61 (SiMe-C), 14.22 (6'-C), 17.86 (TBS tBu-tC), 25.64 (tBu-C), 27.09 (tBu-C), 28.96 (5'-C), 38.86 (Piv tBu-tC), 40.48 (2'-C), 58.38 (5-CH₂O-C), 74.27 (3'-C), 84.26 (4'-C), 85.84 (1'-C), 109.99 (5-C), 118.95 (7'-C), 141.07 (6-C), 149.64 (2-C), 162.27 (4-C), 178.77 (Piv CO-C). ESI-HRMS for [C₂₃H₃₇N₃O₆Si + H]⁺ calcd, 480.2530; found, 480.2535.

(1-((2R,4S,5R)-5-(2-cyanoethyl)-4-hydroxytetrahydrofuran-2-yl)-2,4-dioxo-1,2,3,4-

tetrahydropyrimidin-5-yl)methyl pivalate (44): Following the synthetic procedure

described for compound 21, compound **43** (80 mg, 0.17 mmol) afforded product **44** as a white solid (55 mg, 90%). ¹H NMR (300 MHz, CD₃OD) δ ppm 1.18 (s, 9H, tBu), 1.92 - 2.06 (m, 1H, 5'-H) 2.06 - 2.16 (m, 1H, 5'-H), 2.29 (dd, *J* = 6.59, 5.71 Hz, 2H, 2'-H), 2.52 - 2.71 (m, 2H, 6'-H), 3.87 (dt, *J* = 9.01, 4.43 Hz, 1H, 4'-H), 4.17 - 4.24 (m, 1H, 3'-H), 4.84 (s, 2H, 5-CH₂O), 6.20 (t, *J* = 6.59 Hz, 1H, 1'-H), 7.78 (s, 1H, 6-H). ¹³C NMR (75 MHz, CD₃OD) δ ppm 14.51 (6'-C), 27.53 (tBu-C), 30.37(5'-C), 39.90 (tBu-tC), 40.30 (2'-C), 60.22 (5-CH₂O), 74.70 (3'-C), 86.05 (4'-C), 86.85 (1'-C), 110.70 (5-C), 120.82 (7'-C), 143.01 (6-C), 151.87 (2-C), 164.85 (4-C), 180.09 (Piv CO-C). ESI-HRMS for [C₁₇H₂₃N₃O₆ + H]⁺ calcd, 366.1665; found, 366.1631.

3-((2R,3S,5R)-3-hydroxy-5-(5-(hydroxymethyl)-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)tetrahydrofuran-2-yl)propanenitrile (30): A solution of 0.5M NaOMe in methanol (0.7 mL, 0.342 mmol) was added to compound **44** (25 mg, 0.068 mmol) and stirred at room temperature for 3h. Acetic acid (30 μ L, 0.5 mmol) was added and the solvents were evaporated. The residue was purified by flash column chromatography (4-8% MeOH in CH₂Cl₂) to afford **30** as a white solid (19 mg, 95%). ¹H NMR (300 MHz, DMSO-*d*₆) δ ppm 1.76 - 1.90 (m, 1H, 5'-H), 1.90 - 2.03 (m, 1H, 5'-H), 2.06 - 2.25 (m, 2H, 2'-H), 2.53 - 2.68 (m, 2H, 6'-H), 3.72 (dt, *J* = 8.49, 4.54 Hz, 1H, 4'-H), 4.05 - 4.13 (m, 1H, 3'-H), 4.16 (s, 2H, 5-CH₂O), 4.97 (brs, 1H, 5-MeOH), 5.39 (brs, 1H, 3'-OH), 6.16 (t, *J* = 6.74 Hz, 1H, 1'-H), 7.42 (s, 1H, 6-H), 11.34 (brs, 1H, NH). ¹³C NMR (75 MHz, DMSO-*d*₆) δ ppm 13.21 (6'-C), 28.53 (5'-C), 38.36 (2'-C), 55.70 (5-CH₂O-C), 72.53 (3'-C), 83.87 (1'-C), 83.97 (4'-C), 114.46 (5-C), 120.17 (7'-C), 136.38 (6-C), 150.13 (2-C), 162.42 (4-C). ESI-HRMS for [C₁₂H₁₅N₃O₅ + HCOO]⁻ calcd, 326.0988; found, 326.0985.

(1-((2R,4S,5R)-5-(2-(1H-tetrazol-5-yl)ethyl)-4-((tert-butyl)dimethylsilyloxy)tetrahydrofuran-2-yl)-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-5-yl)methyl pivalate (45): Following the procedure described for the synthesis of **22**, compound **43** (80 mg, 0.17 mmol) rendered **45** as white solid (74 mg, 74 %). ¹H NMR (300 MHz, CDCl₃) δ ppm 0.08 (s, 6H, SiMe), 0.89 (s, 9H, TBS tBu), 1.24 (s, 9H, Piv tBu), 1.74 - 1.91 (m, 1H, 5'-H), 2.04 - 2.17 (m, 1H, 2'-H), 2.19 - 2.33 (m, 1H, 5'-H), 2.39 (ddd, *J* = 13.55, 5.93, 3.95 Hz, 1H, 2'-H), 3.13 - 3.28 (m, 2H, 6'-H), 4.03 (dt, *J* = 10.69, 3.00 Hz, 1H, 4'-H), 4.10 - 4.18 (m, 1H, 3'-H), 4.93 - 5.08 (m, 2H, 5-CH₂O), 6.21 (t, *J* = 6.30 Hz, 1H, 1'-H), 7.79 (s, 1H, 6-H), 8.99 (brs, 1H, NH). ¹³C NMR (75 MHz, CDCl₃) δ ppm -4.83, -4.66 (SiMe-C),

17.95 (TBS tBu-tC), 20.40 (6'-C), 25.68 (tBu-C), 27.12 (tBu-C), 33.34 (5'-C), 39.38 (Piv tBu-tC), 40.56 (2'-C), 59.14 (5-CH₂O-C), 75.13 (3'-C), 86.66 (4'-C), 87.00 (1'-C), 109.27 (5-C), 142.20 (6-C), 149.73 (2-C), 155.28 (7'-C), 162.27 (4-C), 182.48 (Piv CO-C). ESI-HRMS for [C₂₃H₃₈N₆O₆Si - H]⁻ calcd, 521.2544; found, 521.2551.

1-((2R,4S,5R)-5-(2-(1H-tetrazol-5-yl)ethyl)-4-((tert-butyl)dimethylsilyloxy)tetrahydrofuran-2-yl)-5-(hydroxymethyl)pyrimidine-2,4(1H,3H)-dione (46): Following the procedure described for the synthesis of **30**, compound **45** (90 mg, 0.17 mmol) after chromatography (5-7 % MeOH + 0.5 % HCOOH in CH₂Cl₂) rendered **46** as white solid (70 mg, 92 %). ¹H NMR (300 MHz, CD₃OD) δ ppm 0.11 (s, 6H, SiMe), 0.91 (s, 9H, tBu), 2.00 - 2.12 (m, 1H, 5'-H), 2.12 - 2.38 (m, 3H, 2' & 5'-H), 2.99 - 3.19 (m, 2H, 6'-H), 3.82 (dt, *J* = 9.37, 4.10 Hz, 1H, 4'-H), 4.31 (dt, *J* = 6.00, 4.32 Hz, 1H, 3'-H), 4.35 (d, *J* = 1.17 Hz, 2H, 5-CH₂O), 6.20 (t, *J* = 6.74 Hz, 1H, 1'-H), 7.53 (s, 1H, 6-H). ¹³C NMR (75 MHz, CD₃OD) δ ppm -4.70, -4.50 (SiMe-C), 18.80 (tBu-tC), 21.38 (6'-C), 26.25 (tBu-C), 32.52 (5'-C), 40.87 (2'-C), 57.80 (5-CH₂O-C), 76.34 (3'-C), 86.61 (1'-C), 87.00 (4'-C), 115.70 (5-C), 138.70 (6-C), 152.12 (2-C), 158.26 (7'-C), 165.00 (4-C). ESI-HRMS for [C₁₈H₃₀N₆O₅Si - H]⁻ calcd, 437.1969; found, 437.1982.

1-((2R,4S,5R)-5-(2-(1H-tetrazol-5-yl)ethyl)-4-hydroxytetrahydrofuran-2-yl)-5-(hydroxymethyl)pyrimidine-2,4(1H,3H)-dione (47): In a polypropylene vessel, to a solution of compound **46** (70 mg, 0.16 mmol) in methanol (10 mL) was added NH₄F (120 mg, 3.2 mmol) and stirred at 50 °C for 2 days. Dichloromethane (10 mL) was added and filtered. The filtrate was concentrated and the residue purified by flash column chromatography (8-12 % MeOH + 0.5% HCOOH in CH₂Cl₂) to afford **47** as a white solid (45 mg, 87%). ¹H NMR

(300 MHz, DMSO- d_6) δ ppm 1.88 - 2.01 (m, 1H, 5'-H), 2.01 - 2.24 (m, 3H, 5' & 2'-H), 2.86 - 3.05 (m, 2H, 6'-H), 3.65 - 3.75 (m, 1H, 4'-H), 4.05 - 4.13 (m, 1H, 3'-H), 4.16 (d, $J = 0.88$ Hz, 2H, 5-CH₂O), 6.15 (t, $J = 6.74$ Hz, 1H, 1'-H), 7.44 (s, 1H, 6-H), 11.35 (brs, 1H, NH). ¹³C NMR (75 MHz, DMSO- d_6) δ ppm 19.65 (6'-C), 30.89 (5'-C), 38.63 (2'-C), 55.69 (5-CH₂-C), 72.77 (3'-C), 83.60 (1'-C), 84.50 (4'-C), 114.48 (5-C), 136.18 (6-C), 150.14 (2-C), 155.96 (7'-C), 162.42 (4-C). ESI-HRMS for [C₁₂H₁₆N₆O₅ - H]⁻ calcd, 323.1104; found, 323.1234.

SUPPORTING INFORMATION

¹H and ¹³C NMR spectra of all the final compounds are available.

REFERENCES

1. (a) Mdluli, K.; Spigelman, M. *Current Opinion in Pharmacology*, **2006**, *6*, 459–467.
(b) Lamichhane, G. *Trends in Molecular Medicine* **2011**, *17*, 25-33.
2. (a) Villemagne, B.; Crauste, C.; Flipo, M.; Baulard, A. R.; Déprez, B.; Willand, N. *Eur. J. Med. Chem.*, **2012**, *51*, 1-16. (b) Koul, A.; Arnoult, E.; Lounis, N.; Guillemont, J.; Andries, K. *Nature* **2011**, *469*, 483-490.
3. Keating, T. A. ; Newman, J. V. ; Olivier, N. B., Otterson, L. G. ; Andrews B. ; Boriack-Sjodin, P. A. ; Breen, J. N. ; Doig, P. ; Dumas, J. ; Gangl, E. ; Green, O. M. ; Guler, S. Y. ; Hentemann, M. F. ; Joseph-McCarthy, D. ; Kawatkar, S. ; Kutschke, A. ; Loch, J. T. ; McKenzie, A. R. ; Pradeepan, S.; Prasad, S. ; Martínez-Botella, G. *ACS Chem Biol.* **2012**, Aug 28. [Epub ahead of print]
4. (a) Van Calenbergh, S.; Pochet, S.; Munier-Lehmann, H. *Curr. Top. Med. Chem.*, **2012**, *12*, 694-705. (b) Van Poecke, S.; Munier-Lehmann, H.; Helyneck, O.; Froeyen, M.; Van Calenbergh, S. *Bioorg. Med. Chem.* **2011**, *19*, 7603-7611.
5. Haouz, A.; Vanheusden, V.; Munier-Lehmann, H.; Froeyen, M.; Herdewijn, P.; Van Calenbergh, S.; Delarue, M. *J. Biol. Chem.* **2003**, *278*, 4963-4971.

6. Frecer, V.; Seneci, P.; Miertus, S. *J. Comput. Aided Mol. Des.* **2011**, *25*, 31–49.
7. Amewu, R.; O'Neill, P. M.; Stachulski, A.; Ellis, G.; Ward, S. A. *WO* 2008/038030.
8. Mazur, W. A.; He, Y.; Sorekin, V. *WO* 2010/072831.
9. Song, Y.; Liu, C-I.; Lin, F. Y.; No, J. H.; Hensler, M.; Liu, Y. L.; Jeng, W.; Low, J.; Liu, G. Y.; Nizet, V.; Wang, A. J-H.; Oldfield, E. *J. Med. Chem.* **2009**, *52*, 3869–3880.
10. Grover, R. K.; Pond, S. J. K.; Cui, Q.; Subramaniam, P.; Case, D. A.; Millar, D. P.; Wentworth, Jr. P. *Angew. Chem. Int. Ed.* **2007**, *46*, 2839–2843.
11. Evano, G.; Schaus, J. V.; Panek, J. S. *Org. Lett.* **2004**, *6*, 525-528.
12. (a) Satoh, T.; Nanba, K.; Suzuki, S. *Chem. Pharm. Bull.* **1971**, *19*, 817. (b) Yadav, J. S.; Yadav, N. N.; Rao, T. S.; Reddy, B. V. S.; Ghamdi, A. A. K. A. *Eur. J. Org. Chem.* **2011**, 4603–4608.
13. Rhodes, R. A.; Boykin, D. W. *Synth. Commun.* **1988**, *18*, 681-687.
14. Saneyoshi, H.; Tamaki, K.; Ohkubo, A.; Seio, K.; Sekine, M. *Tetrahedron* **2008**, *64*, 4370-4376.
15. Kaburagi, Y.; Kishi, Y. *Org. Lett.* **2007**, *9*, 723-726.
16. (a) El Safadi, Y.; Paillart, J-C.; Laumond, G.; Aubertin, A-M.; Burger, A.; Marquet, R.; Vivet-Boudou, V. *J. Med. Chem.* **2010**, *53*, 1534–1545. (b) Shiau, G. T.; Schinazi, R. F.; Chen, M. S.; Prusoff, W. H. *J. Med. Chem.* **1980**, *23*, 127–133. (c) Conte, M. R.; Galeone, A.; Avizonis, D.; Hsu, V. L.; Mayol, L.; Kearns, D. R. *Bioorg. Med. Chem. Lett.* **1992**, *2*, 79-82.
17. Rodrigues-Correia, A.; Koepfel, M. B.; Schäfer, F.; Joshi, K. B.; Mack, T.; Heckel, A. *Anal. Bioanal. Chem.* **2011**, *399*, 441–447.
18. de Kort, M.; de Visser, P. C.; Kurzeck, J.; Meeuwenoord, N. J.; van der Marel, G. A.; Rüger, W.; van Boom, J. H. *Eur. J. Org. Chem.* **2001**, 2075-2082.

19. Tronchet, J. M. J.; Chalard, F.; Rivara-Minten, E.; Seman, M.; De Clercq, E.; Balzarini, J.; Dilda, P. *Nucleosides, Nucleotides & Nucleic Acids* **2002**, *21*, 191-206.